Sun Pharma challenges Israel’s Taro in US courtJune 26th, 2008 - 8:23 pm ICT by IANS
Mumbai, June 26 (IANS) The city-based Sun Pharmaceutical Industries Wednesday filed a lawsuit against Israel’s Taro Pharmaceutical Industries in the New York Supreme Court for the control of the latter’s shares, the company announced here Thursday. Sun also announced that its subsidiary has acquired all shares held by the controlling shareholders of Taro Pharma under an option agreement signed between the two companies.
In a statement, Sun Pharma chairman and managing director Dilip Shanghvi said subsidiaries of Taro Pharma and Sun entered into a merger agreement May 18, 2007. The Taro Pharma board of directors accorded its unanimous approval to this.
At that time, Sun also agreed to invest nearly $60 million in cash to rescue Taro Pharma from bankruptcy.
However, later Taro Pharma’s controlling shareholders, led by its chairman Barrie Levitt, granted Sun an option to acquire all their shares, including all of the founders’ stake in Taro.
Taro Pharma then purported to terminate the merger agreement May 28 this year, an action termed as “improper” by Sun.
Shanghvi explained that the company’s decision to accept Levitt’s proposal was aimed at protecting its interests. He asserted that the company has not recognised the termination of the merger agreement.
He added that Sun will soon initiate a tender offer for all ordinary shares as required by the option agreement. The agreement also requires Sun specifically commence its tender offer at $7.75 per share.
Sun added that Taro Pharma and the non-Levitt family directors, who have not signed the option agreement, filed a case in the Tel Aviv District Court in a bid to delay and block the implementation of the option agreement.
“We have had enough of the delays, excuses and misrepresentations by the board of Taro Pharma and Levitt. We will do everything required to preserve our rights,” Shanghvi said.
- Indian drug major Sun Pharma takes control of Israeli Taro - Sep 22, 2010
- Sun Pharma asks Taro shareholders to vote against board - Dec 18, 2009
- Sun Pharma accuses Israel's Taro of 'accounting gamesmanship' - Jun 25, 2008
- Suzuki Powertrain to merge with Maruti Suzuki - Jun 12, 2012
- Toronto stock exchange kills merger deal with London - Jun 30, 2011
- Kanoria Chemicals to acquire Switzerland-based firm - Apr 20, 2012
- Surya Pharma's arm acquires US's ActivOn for $22 mn - Dec 28, 2010
- Dr.Reddy's acquires JB Chemicals business in Russia - Jul 23, 2011
- Bharti to exit from financial services joint venture with AXA - Jun 10, 2011
- Issues affecting Indian biopharma industry discussed - Jun 10, 2011
- Mahindra Satyam, Tech Mahindra merger likely in 8-9 months - Apr 24, 2012
- Sanofi-aventis makes tender offer of $18.5 billion for Genzyme Corporation - Oct 04, 2010
- Sun Pharma subsidiary gets nod to buy out Israeli firm Taro - Aug 14, 2008
- Reckitt Benckiser to acquire Paras Pharma for $728 mn - Dec 13, 2010
- Automatic approval to FDI in greenfield pharma projects to continue: RBI - Dec 12, 2011
Tags: 60 million, board of directors, founders, levitt, managing director, merger agreement, misrepresentations, mumbai, new york supreme court, option agreement, ordinary shares, shareholders, stake, sun pharma, sun pharmaceutical industries, taro pharmaceutical industries, tel aviv district, tender offer, time sun, unanimous approval